Joe DePinto, MBA, of McKesson; Kathi Henson, MBA, of Orsini; and Natalie Bedford of McKesson discuss how Asembia's AXS25 ...

The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial ...

Patients with moderate to severe chronic spontaneous urticaria that were antihistamine-resistant to omalizumab experienced ...

Sexual minority individuals face countless barriers to health care and are at a heightened risk of unwanted pregnancy.

Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new ...

Innovative financing and reimbursement models can improve access to cell and gene therapies, addressing cost barriers and ...

Antoine Keller, MD, discussed the future impact of technological advances for cardiovascular (CV) care and what other ...

Viral suppression in HIV was more likely to be reported in women in Canada who had adherence to their antiretroviral therapy ...

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

To safely and successfully use artificial intelligence (AI) tools in the pharmacy, credentialing bodies and professional associations will need to validate these tools for the individual pharmacist, ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...